Dipeptidyl peptidase 4 inhibitors may prolong post-AMI survival

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Dipeptidyl peptidase 4 inhibitor (DPP-4i) therapy may improve long-term survival after acute myocardial infarction (AMI) in patients with type 2 diabetes, particularly those without peripheral vascular disease, end-stage renal disease (ESRD), or COPD.

Why this matters

  • Diabete...